The governance structure of ADVANCE has been devised to respond to the needs of the project, its size and complexity. The governance and management structure helps steer the efforts optimally towards the desired results and provides a structure for efficient decision-making with balanced representation of all partners involved in the public-private consortium and its Associate Partners.


Coordination Team
The Coordination Team will be an operative group dealing with the day-to-day issues of the project.

Steering Committee

The Steering Committee will be in charge of the coordination and scientific direction, being responsible for the determination of policies and decision making in relation to the overall running of the project and the initial arbitration of any disputes.

Miriam Sturkenboom, Coordinator, WP5 Co-leader

Jorgen Bauwens, Managing Entity, WP2 Co-leader
University of Basel – University Children’s Hospital

Vincent Bauchau, EFPIA Coordinator, WP1 Co-leader, WP5 Co-leader
GlaxoSmithKline Biologicals

Eva Molero / Natasha Yefimenko, Project Management, WP6 Co-leader
Synapse Research Management Partners

Patrick Mahy*
Scientific Institute of Public Health

Xavier Kurz, WP1 Co-leader
European Medicines Agency

Mendel Haag, WP2 Co-leader
Novartis Pharma AG

Simon de Lusignan, WP3 Co-leader
University of Surrey

Alena Khromava, WP3 Co-leader
Sanofi Pasteur

Kaatje Bollaert, WP4 Co-leader

John Weil, WP4 Co-leader
Takeda Pharmaceutical International AG

Lina Titievsky, WP5 Co-leader
Pfizer Limited

Antonella Chiucchiuini, WP6 Co-leader
Takeda Pharmaceutical International AG

Maarit Kokki / Piotr Kramarz, WP7 leader
European Centre for Disease Prevention and Control

Tin Tin Htar Myint
Pfizer Limited

Patricia Saddier

Laurence Torcel-Pagnon

Tyra Grove*
Statens Serum Institut

Hester de Melker*
Rijksinstituut voor Volksgezondheid en Milieu

*There are two seats for Public Health Institutes in the Steering Committee, which will be rotated between RIVM, WIV-ISP and SSI.

Project Management Office

The Project Management Office will support the successful implementation of this project on a scientific, financial and management level.

General Assembly

The General Assembly is established consisting of a senior representative from each of the participants, being the ultimate decision-making body in the project dealing with matters requiring unanimous decision, and critical issues affecting the project.


The ADVANCE Forum is a common space for wide communication on aspects related to the project. It will comprise all participants in the project, plus Associate Partners, being open to the participation of other key stakeholders.

Ethics Advisory Group

The Ethics Advisory Group will have consultative and review functions on any ethical issue that may arise in work packages 1, 3, 5 and 6, and will advise the Steering Committee on these topics.

Scientific Advisory Board

The Scientific Advisory Board, with consultative functions, will be formed by independent experts external to the project, so that the expertise and knowledge necessary to assist the Steering Committee on scientific grounds is gathered.

Implementability Advisory Board

The Implementability Advisory Board is a selected group of individuals representing organization/bodies who would use the Blueprint and the framework for EU-level vaccine benefit-risk assessment, but who are not participating in the project as participants or Associate Partners